Get all your news in one place.
100’s of premium titles.
One app.
Start reading
Reuters
Reuters
Business

FDA approves blood disorder drug made by Japan's Shionogi

(Reuters) - The U.S. Food and Drug Administration on Tuesday approved Japan-based Shionogi & Co Ltd's treatment for low blood-platelet count or thrombocytopenia in patients with chronic liver disease.

The treatment belongs to a new class of drugs called thrombopoietin receptor agonists (TPO RA), which stimulate platelet production. https://bit.ly/2LJJZPG

Its approval is the second for this class of drug for liver disease patients, following the FDA's greenlight for U.S.-based Dova Pharmaceuticals' rival treatment in May.

(Reporting by Manas Mishra in Bengaluru)

Sign up to read this article
Read news from 100’s of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.